By Fineline Cube 
Harbour BioMed (HKG: 2142) on Aug. 27, 20025 released its first‑half 2025 financial results, reporting a RMB 725 million (≈USD 101 m) revenue – a 327 % year‑on‑year increase – and a RMB 523 million (≈USD 73 m) profit, a 51‑fold rise over the same period last year. Cash reserves climbed to RMB 2.291 billion (≈USD 320 m), up 92 % from the end of 2024.
Financial Highlights
| Metric | H1 2025 | YoY % Change |
|---|---|---|
| Revenue | RMB 725 m | +327 % |
| Net Profit | RMB 523 m | +5 100 % |
| Cash & Cash‑Equivalents | RMB 2.291 b | +92 % |
The results underscore Harbour’s accelerated growth trajectory driven by its portfolio of HCAb‑based bispecific antibodies and expanding commercial partnerships.
Élancé Therapeutics – A New Frontier in Metabolic Disease
In March, Harbour announced the creation of Élancé Therapeutics, a spin‑off that will harness Harbour’s proprietary HCAb platform to develop next‑generation treatments for obesity and related metabolic disorders. The strategy focuses on preserving lean muscle mass and achieving durable weight‑loss efficacy, addressing unmet needs in the current therapeutic landscape.
Strategic Licensing & Collaboration Portfolio
| Month | Partner | Deal | Scope |
|---|---|---|---|
| Jan 2025 | Windward Bio | Global license for HBM9378 / SKB378 (WIN378) | Excludes Greater China, certain SEA & West‑Asia markets |
| Feb 2025 | Insilico Medicine | AI‑powered antibody discovery partnership | Accelerates novel therapeutic discovery |
| Mar 2025 | AstraZeneca | Co‑development of next‑generation multispecific antibodies | Immunological & oncological indications |
| Jun 2025 | Otsuka Pharma | Global collaboration on HBM7020 (BCMAxCD3) | Autoimmune disease pipeline |
These agreements position Harbour to monetize its HCAb technology across a spectrum of indications while expanding its global footprint.
Outlook
Harbour’s robust cash position and pipeline depth provide a strong foundation for continued growth. The company plans to advance Élancé’s obesity program into Phase I by Q3 2026 and expects to further expand its licensing network throughout 2025.-Fineline Info & Tech